3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 来源：新浪证券-红岸工作室 1月5日，采纳股份涨11.05%，成交额1.61亿元，换手率7.53%，总市值35.38亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 该股筹码平均交易成本为27.80元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近压力位 29.73，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。 公司简介 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分 ...

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.84% on December 23, with a trading volume of 55.21 million yuan and a market capitalization of 3.246 billion yuan [1] Group 1: Company Overview - Canar Medical, established on July 23, 2004, is located in Jiangyin, Jiangsu Province, and was listed on January 26, 2022 [7] - The company specializes in the research, production, and sales of medical and veterinary injection and puncture instruments, as well as laboratory consumables [7] - The main revenue sources for Canar Medical are syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86% [7] - The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Position and Trends - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproductive technology sector [2] - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [3] - The stock has seen a recent decrease in major shareholder holdings, with a net outflow of 4.40 million yuan on the day of analysis [4][5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：605369 证券简称：拱东医疗 公告编号：2025-037 浙江拱东医疗器械股份有限公司 关于"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响应上海证券交易所《关于 开展沪市公司"提质增效重回报"专项行动的倡议》，浙江拱东医疗器械股份有限公司（以下简称"公 司"）立足医疗器械行业发展趋势，结合自身核心业务优势、经营实际情况及长远发展战略，基于对公 司未来持续稳定发展的信心和对公司价值的认可，制定本《"提质增效重回报"行动方案》（以下简 称"行动方案"）。旨在通过聚焦主业升级、规范治理运作、优化投资者关系、强化回报机制等举措，持 续提升公司核心竞争力与经营质量，推动公司高质量发展与投资价值提升，切实保护投资者尤其是中小 投资者的合法权益。本次行动方案已于2025年12月22日经公司第三届董事会第十九次会议审议通过，具 体内容如下： 一、聚焦主营业务，提升经营质量 公司 ...

来源：新浪证券-红岸工作室 12月19日，采纳股份跌0.28%，成交额4770.88万元，换手率2.26%，总市值34.28亿元。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 该股筹码平均交易成本为27.84元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近支撑位 27.70，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 公司简介 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 采纳股份所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：融资融券 ...

Core Viewpoint - The company, Canar Medical, has shown a slight increase in stock price and is benefiting from the depreciation of the RMB, particularly in its overseas revenue which constitutes a significant portion of its business [1][3]. Group 1: Company Overview - Canar Medical was established on July 23, 2004, and went public on January 26, 2022. The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7]. - The main revenue components of Canar Medical include syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of November 28, the number of shareholders in Canar Medical is 8,801, a decrease of 2.05% from the previous period, while the average circulating shares per person increased by 2.09% [7]. Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86%. The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On December 18, Canar Medical's stock price increased by 0.43%, with a trading volume of 46.28 million yuan and a turnover rate of 2.17%, resulting in a total market capitalization of 3.44 billion yuan [1]. - The company has been experiencing a net outflow of funds, with a net outflow of 1.05 million yuan on the day of the report, indicating a lack of strong market support [4][5]. Group 4: Technical Analysis - The average trading cost of Canar Medical's shares is 27.83 yuan, with the stock price currently near a support level of 27.75 yuan. There are indications of accumulation, but the strength of this accumulation is weak [6].

来源：新浪证券-红岸工作室 12月16日，采纳股份跌3.28%，成交额7478.06万元，换手率3.46%，总市值34.19亿元。 区间今日近3日近5日近10日近20日主力净流入55.69万489.58万738.57万1493.98万1453.75万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额801.27万，占总成交额的2.39%。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入55.69万，占比0.01%，行业排名27/132，连续2日被主力资金增仓；所属行业主力净流 入-3.47亿，当前无连续增减仓现象，主力趋势不明显。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包 ...

Core Viewpoint - The stock of Canar Medical has seen a significant increase of 4.33% on December 3, with a trading volume of 144 million yuan and a market capitalization of 3.386 billion yuan [1] Group 1: Company Overview - Canar Medical, established on July 23, 2004, is located in Jiangyin, Jiangsu Province, and was listed on January 26, 2022 [7] - The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7] - The main revenue sources for the company are syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86% [7] - The net profit attributable to the parent company was 8.25 million yuan, showing a significant decline of 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Dynamics - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproductive technology sector [2] - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the Chinese yuan [3] - The stock has seen a net inflow of 15.7 million yuan from major investors today, marking a continuous increase in investment over the past three days [4][5]

Core Viewpoint - The company, Canan Technology Co., Ltd., is experiencing fluctuations in stock performance and is benefiting from the depreciation of the RMB, particularly in its overseas revenue streams. Group 1: Company Overview - Canan Technology was established on July 23, 2004, and went public on January 26, 2022. The company is located in Jiangyin, Jiangsu Province, and specializes in the R&D, production, and sales of medical and veterinary injection and puncture instruments, as well as laboratory consumables [7]. - The main revenue components of the company include syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7]. - As of November 20, the number of shareholders increased by 14.36% to 8,985, while the average circulating shares per person decreased by 12.55% to 8,418 shares [7]. Group 2: Financial Performance - For the period from January to September 2025, the company reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86%. The net profit attributable to the parent company was 8.25 million yuan, down 85.64% year-on-year [7]. - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8]. Group 3: Market Activity - On November 26, the stock price of Canan Technology increased by 0.04%, with a trading volume of 59.69 million yuan and a turnover rate of 3.00%. The total market capitalization stands at 3.181 billion yuan [1]. - The company has seen a net inflow of 3.75 million yuan from major investors today, ranking 19th out of 132 in its industry, with a continuous increase in major investor positions over the past three days [4][5]. Group 4: Technical Analysis - The average trading cost of the stock is 27.79 yuan, with recent rapid outflows of shares suggesting a recommendation for portfolio adjustment. The current stock price is fluctuating between a resistance level of 27.16 yuan and a support level of 24.61 yuan, indicating potential for range trading [6]. Group 5: Industry Context - The company operates within the medical device sector, specifically focusing on medical consumables, and is positioned to benefit from trends in assisted reproduction and medical device markets, particularly due to its supply relationship with Thermo Fisher since 2018 [2][3].

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.92% on November 21, with a trading volume of 81.41 million yuan and a total market capitalization of 3.115 billion yuan [1] Group 1: Company Overview - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018 [2] - The company's main business involves the research, production, and sales of injection and puncture instruments as well as laboratory consumables, with key products including puncture needles, syringes, laboratory consumables, and masks [2] - As of November 20, the number of shareholders in Canar Medical was 8,985, an increase of 14.36% from the previous period, while the average circulating shares per person decreased by 12.55% [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Dynamics - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the yuan [3] - The average trading cost of the stock is 27.89 yuan, with recent rapid outflows of shares suggesting a recommendation for portfolio adjustment [6]

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.70% on November 20, with a trading volume of 1.11 billion yuan and a market capitalization of 3.242 billion yuan [1] Group 1: Company Overview - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018 [2] - The company specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2] - As of October 31, the number of shareholders in Canar Medical was 7,857, an increase of 4.11% from the previous period, with an average of 9,627 circulating shares per person, a decrease of 3.95% [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Position and Trends - The company benefits from a high overseas revenue ratio, with 90.61% of its revenue coming from international markets, positively impacted by the depreciation of the yuan [3] - The average trading cost of the stock is 27.92 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6] - The stock is approaching a resistance level of 27.05 yuan, indicating potential for a pullback unless this level is breached, which could trigger an upward trend [6]